An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

NCT00960076 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

282

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Saxagliptin
DRUG: Metformin XR
DRUG: Metformin XR

Sponsor

AstraZeneca

Collaborators

[object Object]